What Is Skeletal Muscle Index and Why Does It Matter?

Skeletal muscle index, or SMI, is a standardized measure of how much muscle you carry relative to your body size. It is calculated by dividing skeletal muscle area or mass by height squared, producing a number that lets clinicians compare muscle quantity across people of different builds. The reason it matters goes well beyond fitness: a growing body of research links low SMI to higher death rates, worse cancer treatment outcomes, surgical complications, metabolic disease, and fragility in older age. What started as a niche research metric has become one of the more useful tools medicine has for predicting how well your body can handle serious illness.

How Skeletal Muscle Index Is Calculated

The basic idea behind SMI is simple. You measure how much skeletal muscle someone has, then adjust for their height so that a tall person and a short person with proportionally the same musculature get comparable scores. In clinical research, the most common version uses a cross-sectional CT scan taken at the level of the third lumbar vertebra (L3), a spot in the lower back where a single image slice reliably reflects total-body muscle. Software measures the total skeletal muscle area in that slice in square centimeters, divides it by height in meters squared, and the result is your SMI in cm²/m².

A related version, the appendicular skeletal muscle index (aSMI), works from muscle mass in the arms and legs rather than a single CT slice. This is typically measured using DXA, the same type of scan used for bone density. The limb muscle masses are summed and divided by height squared, producing a value in kg/m².¹ Both approaches capture the same underlying concept, but the numbers are not interchangeable because they measure different things (area of one slice versus mass of four limbs). When you see SMI values in a study, it matters which version was used.

What Counts as Low

Cutoff values for sarcopenia, the clinical term for dangerously low muscle mass, differ by sex because men typically carry more muscle. One large study using CT scans of healthy Americans found that sarcopenia cutoffs at the L3 level were about 45.4 cm²/m² for men and 34.4 cm²/m² for women.² Fall below those thresholds and you are in the range where muscle loss starts predicting worse health outcomes. For the appendicular version using DXA, organizations like the Foundation for the National Institutes of Health have proposed different thresholds, defining low muscle as an appendicular lean mass-to-BMI ratio below 0.789 for men and 0.512 for women.³

These cutoffs are not perfect, and one of the ongoing challenges in the field is that different research groups use different thresholds, different imaging methods, and different adjustment strategies, making it hard to compare results across studies. That said, the direction of the evidence is consistent: the less muscle you have relative to your frame, the worse your prognosis across a wide range of conditions.

The Mortality Connection

The most striking reason SMI has gained attention is its relationship with death. A systematic review and meta-analysis of prospective studies found that people with the lowest skeletal muscle mass had roughly 57% higher risk of dying from any cause compared to those with normal muscle mass.⁴ That is a substantial increase in risk, comparable to the mortality impact of some well-known conditions.

A large U.S. study looking at appendicular muscle mass across quintiles found a dose-response pattern: more muscle meant lower mortality. Each 20-percentile increase in SMI was associated with a 14% lower risk of all-cause death after adjusting for age, race, BMI, and major chronic diseases.⁵ A 12-year prospective study of older adults similarly found that low height-adjusted SMI predicted higher mortality, and the risk climbed further when low muscle mass was paired with poor physical performance measures like weak grip strength or slow walking speed.⁶

The picture gets even starker when you combine low muscle with high fat. Sarcopenic obesity, having both low muscle mass and excess body fat, carries an especially grim prognosis. A study in JAMA Network Open found that people with sarcopenic obesity and two altered body composition markers had nearly triple the mortality risk compared to those without the condition.⁷ This is the combination clinicians worry about most, because it is easy to miss: someone can look like they weigh a normal or even high amount while secretly lacking the muscle needed to weather a health crisis.

Why Muscle Mass Declines With Age

People begin losing skeletal muscle mass gradually starting in their 30s or 40s, at a rate of roughly 1% per year from middle age onward. In severe cases, total muscle loss can reach about 50% by the eighth or ninth decade of life.⁸ Two mechanisms drive this: individual muscle fibers shrink (atrophy), and the total number of muscle fibers decreases (a process called hypoplasia). The shrinkage appears largely driven by what researchers call anabolic resistance, where aging muscles become less responsive to the signals from food and exercise that normally trigger muscle repair and growth. Your body still builds and breaks down muscle protein on a daily cycle, but the building side gradually loses its edge.

Men lose absolute muscle mass at roughly double the rate of women, partly because they start with more of it. Early research on appendicular muscle mass confirmed that the absolute decline with age was significantly larger in men, though both sexes followed the same general pattern.⁹ This is one reason sarcopenia cutoffs are sex-specific: a 70-year-old woman with an SMI that would be alarming in a man may be within a normal range for her.

Muscle Mass and Cancer Treatment

One of the areas where SMI has had the most practical impact is oncology. Cancer patients with low muscle mass tolerate chemotherapy and other treatments poorly, and SMI gives oncologists a way to quantify that risk before treatment begins. A meta-analysis pooling data from dozens of studies found that patients with low skeletal muscle mass had about two to two-and-a-half times the odds of experiencing dose-limiting toxicity, whether they were receiving curative or palliative chemotherapy.¹⁰ The relationship was even stronger for certain targeted therapies like kinase inhibitors, where the odds of severe side effects roughly tripled for patients with low muscle.

A study of metastatic breast cancer patients on taxane-based chemotherapy illustrates the clinical stakes. Sarcopenic patients experienced severe (grade 3-4) toxicity at three times the rate of non-sarcopenic patients. They also had more hospitalizations and adverse events overall.¹¹ There is even evidence that muscle mass affects drug metabolism directly: patients with lower SMI at specific muscle groups showed higher rates of certain chemotherapy side effects like nerve damage and fatigue, likely because the drug concentrates differently when there is less muscle tissue to absorb and process it.¹²

This has real consequences for treatment decisions. Some oncologists are beginning to use SMI as one factor when deciding whether to adjust chemotherapy doses for patients who might not tolerate standard regimens. The idea is straightforward: if someone’s muscle reserve is already depleted, hitting them with a full drug dose calibrated to body surface area alone could cause more harm than benefit.

Surgical Risk

Surgeons face a similar problem. Patients going into major operations with low muscle mass tend to have more complications afterward, heal more slowly, and spend longer in the hospital. A study of Crohn’s disease patients undergoing surgery found that those with an SMI below 38.9 cm²/m² had nearly triple the odds of postoperative complications compared to patients with higher muscle mass, making it one of the strongest independent predictors of a rough recovery.¹³ Similar findings have been reported across many surgical specialties, from liver transplant to colorectal and cardiac surgery.

The practical appeal for surgeons is that CT scans are already routine before many major operations, and measuring SMI from an existing scan adds no extra cost or radiation. It gives the surgical team one more piece of information when weighing the risks and benefits of proceeding, or when deciding whether a patient might benefit from a period of “prehabilitation,” targeted exercise and nutrition to build up muscle reserves before the operation.

Metabolic Health Beyond the Muscles

Skeletal muscle is the body’s largest organ for glucose disposal. When you eat carbohydrates, your muscles absorb a large share of the resulting blood sugar. Less muscle means less metabolic sponge, which helps explain why low muscle mass is linked to insulin resistance and diabetes. In a Korean population study, sarcopenia roughly doubled the risk of diabetes and metabolic syndrome in non-obese individuals, particularly among older adults.¹⁴ That last detail is important: the connection showed up most clearly in people who were not overweight, suggesting that muscle loss is a metabolic risk factor independent of obesity.

The metabolic link extends to the liver. Multiple meta-analyses have found that sarcopenic individuals have a roughly 30 to 50% higher risk of nonalcoholic fatty liver disease (NAFLD), and the risk of advanced liver scarring is even more elevated. A longitudinal study of over 12,000 participants found that those with the highest muscle mass had less than half the risk of developing NAFLD compared to those with the lowest, and gaining muscle over time was associated with resolution of existing fatty liver disease.¹⁵ Since no drugs are approved specifically for NAFLD treatment, building muscle has emerged as one of the more promising interventions.

Bones, Falls, and Osteosarcopenia

Muscle and bone deteriorate in tandem more often than you might expect. When someone has both sarcopenia (low muscle) and osteoporosis (weak bones), the combined condition is called osteosarcopenia, and the consequences are worse than either condition alone. A cross-sectional analysis of adults over 50 found that osteosarcopenic patients had significantly lower bone density, higher rates of major fractures, and more falls than those with osteoporosis alone. Hip fracture rates were about three times higher in osteosarcopenic patients compared to controls, and over 40% of the osteosarcopenic group had experienced a fall in the past year.¹⁶

Screening recommendations increasingly suggest evaluating both muscle and bone together in older adults at risk. SMI is one of the tools that can flag the muscle side of this equation, alongside questionnaires and functional tests like grip strength and walking speed.¹⁷ The logic is that catching muscle loss early creates a window to intervene before the combination of weak bones and weak muscles turns a stumble into a catastrophic fracture.

Ethnic Variation and the Problem of Universal Cutoffs

One complication in using SMI clinically is that “normal” muscle mass varies by ethnicity. Studies have consistently shown that, at similar height and weight, African Americans tend to have the highest skeletal muscle mass, followed by White, Hispanic, and Asian populations.¹⁸ These are not small differences. A comparison across ethnic groups found that at the same BMI, fat distribution, total muscle mass, and regional muscle partitioning all varied, meaning a single cutoff for “low” SMI will overdiagnose sarcopenia in some populations and miss it in others.¹⁹

This remains one of the more contentious issues in sarcopenia research. Most widely used cutoffs were derived from predominantly White populations, and applying them universally risks systematic errors. The field is moving toward ethnic-specific reference ranges, but adoption has been slow, partly because generating accurate cutoffs requires large, well-characterized datasets from each population.

How SMI Is Actually Measured

Three imaging methods dominate. CT scanning at the L3 level is the gold standard in research and is especially convenient for patients already getting abdominal scans for other reasons, such as cancer staging. MRI can also measure muscle precisely but is more expensive and less commonly used for this purpose. DXA, the standard bone density scan, is the most practical option in outpatient settings because it measures whole-limb muscle mass with low radiation and moderate cost.

Bioelectrical impedance analysis (BIA), the technology used in many consumer body-composition scales, offers the cheapest and most portable option. It works by sending a tiny electrical current through the body and estimating muscle based on how the current travels. While BIA correlates with CT-derived measurements, the agreement between the two is imperfect. A study comparing CT-based body composition to BIA found reasonable correlation overall, but the concordance was limited, meaning BIA can track trends within the same person over time but may not match the absolute accuracy of imaging.²⁰ For population-level screening and tracking, BIA is useful. For precise clinical decisions like chemotherapy dosing or surgical risk stratification, imaging is preferred.

A recent development is the use of deep learning algorithms to automatically segment muscle on CT scans. These tools can identify and measure muscle area from abdominal scans with high accuracy, producing results that closely match expert human analysis. One pediatric-focused system achieved a mean accuracy of 93% on muscle segmentation, bringing automated SMI measurement closer to routine clinical use.²¹ The appeal is obvious: if muscle measurement can be pulled automatically from scans that hospitals are already performing, SMI could become a standard vital sign rather than a research curiosity.

Can You Improve Your SMI?

The encouraging news is that muscle loss is not a one-way street, at least not entirely. Resistance training remains the most reliable intervention for improving SMI in people with age-related sarcopenia. A meta-analysis found that resistance training significantly improved grip strength, walking speed, and skeletal muscle index in elderly sarcopenic patients. Elastic band training performed for 40 to 60 minutes per session, at least three times a week for 12 weeks or more, emerged as the most consistently supported exercise prescription across multiple studies.²² That finding is worth noting because elastic bands are cheap, portable, and low-risk for frail older adults who might not be able to handle heavy weights safely.

Nutrition plays a supporting role. Adequate protein intake is important for maintaining the muscle-building signals that aging blunts. Some amino acids and amino acid-derived compounds like creatine and taurine have shown promise in improving muscle mass and function in older adults.²³ The combination of resistance training with sufficient protein appears to be more effective than either alone, though research continues to refine optimal doses and timing.

SMI in Children and Younger Adults

While most attention has focused on older adults, muscle mass assessment is gaining ground in pediatric medicine as well. Children with chronic diseases like cancer, inflammatory bowel disease, or organ failure can develop sarcopenia, but until recently there were no good reference ranges to compare against. Researchers have used automated deep learning tools on large sets of pediatric CT scans to establish normal age- and sex-based SMI values for children, identifying those who fall below the 5th percentile as potentially sarcopenic.²⁴ This is an early-stage effort, but it opens the door to catching muscle wasting earlier in sick children, where nutritional support and physical therapy could potentially change outcomes.

Drugs Targeting Muscle Wasting

Exercise and nutrition help, but for patients who are too ill to exercise or whose muscle wasting is driven by aggressive disease, pharmaceutical options are being explored. One of the most studied targets is myostatin, a protein the body produces that naturally limits muscle growth. Blocking myostatin in animal models of muscle wasting has increased muscle volume, and several inhibitors have entered clinical trials showing initial positive effects on muscle mass.²⁵ Progress has been slower than hoped, partly because increasing muscle size does not always translate neatly into improved strength or function, and partly because the regulatory pathway for approving muscle-wasting treatments is not straightforward. But for patients with severe cancer-related cachexia or other conditions where muscle is wasting rapidly, pharmacological intervention could eventually complement what exercise alone cannot achieve.